Illumina and Thermo Fisher Scientific are the Leading Player in the Metagenomic Sequencing Market4/22/2022 Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields.
The Metagenomic sequencing market is expected to reach USD 4.3 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 18.4% during the forecast period. Download PDF Brochure :-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=60408643 Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), and Oxford Nanopore Technologies Plc. (UK) are the prominent players operating in the metagenomic sequencing market. Illumina (US) is the leading player in the metagenomic sequencing market, accounting for the largest share of the market in 2020. This is attributed to its robust product offerings and NGS services. The company’s product segment includes a wide range of sequencing, genotyping, gene expression, and molecular diagnostic platforms, consumables, and services that run on SBS technology. In the past three years, Illumina has launched several products in the market, including the NovaSeqT 6000 v1.5 Reagent Kit, TruSight Software Suite, NextSeq 1000, and NextSeq 2000. To ensure continuous product development, the company invests a significant amount of its revenue on R&D. It also focuses on agreements with leading players to co-develop advanced technologies and strengthen its research & commercialization capabilities. In the past three years, Illumina has entered into agreements with Helix OpCo, LLC (US), Roche (Switzerland), and QIAGEN (Netherlands). Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=60408643 Thermo Fisher Scientific (US) held the second position in the metagenomic sequencing market in 2020. The company’s NGS sequencers run on Ion Semiconductor sequencing technology. Thermo Fisher will continue to have a strong market position owing to its robust platforms and consumables offerings. The company also has a significant geographic presence. It adopts organic and inorganic strategies such as collaborations, partnerships, and product launches to strengthen its market position. For instance, in September 2021, it codeveloped NGS-based companion diagnostics with AstraZeneca.
0 Comments
Increasing government funding for cell-based research and the rising incidence of chronic and infectious diseases are the major factors driving the growth of this market.
The Cell Analysis Market is expected to reach USD 22.7 billion by 2024 from USD 16.0 billion in 2019, at a CAGR of 7.2%. from 2019 to 2024 Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157543946 Market Segmentation:- Based on product, the cell analysis market is broadly categorized into microscopes, flow cytometry products, spectrophotometers, qPCR products, cell counters, cell microarrays, high-content screening (HCS) systems, and other products. The flow cytometry products segment accounted for the largest market share in 2018. The large share of this segment is primarily attributed to technological advancements, the increasing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the field of immunology and immuno-oncology research, and the rising incidence and prevalence of chronic diseases. Based on end user, the cell analysis market is segmented into hospitals & diagnostic laboratories, research institutes, pharmaceutical & biotechnology companies and CROs, cell culture collection repositories, and other end users. The pharmaceutical & biotechnology companies and CROs segment is expected to register the highest CAGR during the forecast period. These facilities use cell analysis instruments and consumables during various stages of drug discovery, drug research and development, pharmacokinetics, toxicology, and clinical studies. Growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical R&D expenditure, and commercial expansion of various pharmaceutical companies are driving the growth of this end-user segment. Regional Analysis: - By region, the cell analysis market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2018, North America accounted for the largest market share, followed by Europe. Factors such as the presence of a favorable business environment, growing government support through funds and grants, growing number of research activities, rising number of drug discovery initiatives by pharmaceutical & biotechnology companies in the US, and the strong presence of key players in this region are driving the growth of the cell analysis market in North America. Request for Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=157543946 Top Key Players:- The prominent players operating in the cell analysis market are Danaher Corporation (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck KGaA (Germany), GE Healthcare (US), Agilent Technologies, Inc. (US), Olympus Corporation (Japan), PerkinElmer, Inc. (US), Promega Corporation (US), Tecan Group (Switzerland), Miltenyi Biotec (Germany), Carl Zeiss (Germany), Bio-Rad Laboratories Inc (US), and Sysmex Corporation (Japan). Animal health products, including growth promoters and performance enhancers, are types of drugs and chemicals used for animal growth. These enhancers help to digest food more effectively and enable animals to grow faster, which, in turn, help to improve productivity. Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising animal epidemics and climate change. However, a ban on antibiotics in different nations and stringent regulations restricting the use of antibiotics and hormones for growth promotion in animals are expected to restrain the growth of the animal growth promoters and performance enhancers market during the forecast period.
The global Animal growth promoters and performance enhancers market is projected to reach USD 21.4 billion by 2026 from USD 16.2 billion in 2021, at a CAGR of 5.7%. Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137134167 The global animal growth promoters and performance enhancers market are Cargill, Incorporated (US), Royal DSM N.V. (Netherlands), Elanco Animal Health Incorporated (US), Boehringer Ingelheim Group (Germany), Merck & Co., Inc (US), Alltech Corporation (US), Archer-Daniels-Midland Company (ADM) (US), Vetoquinol S.A. (France), Bupo Animal Health Pty Ltd (South Africa), Novus International, Inc. (US), Associated British Foods plc (UK), Erber AG (Austria), Phibro Animal Health Corporation (US), Kemin Industries, Inc. (US), Zoetis Inc. (US), Nutreco N.V. (Netherlands), Novozymes A/S (Denmark), BASF SE (Germany), Evonik Industries AG (Germany), Bluestar Adisseo Company (China), Land O’Lakes, Inc. (US), Chr. Hansen (Denmark), Biomin Holding GmbH (Austria), Guangdong VTR Bio-Tech Co., Ltd. (China), and Lallemand Inc. (Canada). These companies adopted strategies such as acquisitions, partnerships, expansions, and product launches to enhance their presence in the animal growth promoters and performance enhancers market. Cargill, Incorporated. is a key player in the market, and animal growth promoters and performance enhancers are two major sources of revenue for the company. This segment is the strongest performing segment as well as the largest contributor to the company’s revenue. Cargill brings innovative solutions to animal producers, feed manufacturers, and retailers in the animal growth promoters and performance enhancers market. It provides the Cargill Nutrition System, which provides a real-time nutrient analysis of feed ingredients, as well as information from the company’s global ingredient sourcing database. This helps animal producers plan nutrition diets for animals, and the database assists producers on demand in case of any queries. Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=137134167 Royal DSM N.V. is a prominent player in the animal growth promoters and performance enhancers market. Its leading position among other players in this market can be attributed to its wide product portfolio that includes growth promoters and performance enhancers, such as RONOZYME WX, ROVIMAX NX, Optimum Vitamin Nutrition (OVN). The company has a wide geographic presence spanning Europe and Latin America. Browse Related Reports: Animal Antibiotics and Antimicrobials Market by Product (Tetracycline, Penicillin, Sulfonamide, Macrolide, Cephalosporin, Lincosamide), Mode of Delivery (Premixes, Oral Solution, Injection), Animal (Food producing & Companion) - Global Forecast to 2026 https://www.marketsandmarkets.com/Market-Reports/animal-antimicrobials-antibiotics-market-25161353.html The global High-performance Liquid Chromatography (HPLC) Market size is projected to reach USD 5.7 billion by 2025 from USD 4.5billion in 2020, at a CAGR of 4.6% during the forecast period. The growth in this market is driven byhigh sensitivity and accuracy of the HPLC technique, the growing importance of HPLC tests in drug approvals,the rising popularity of hyphenated techniques, and increasing pharmaceutical R&D spending. However, the high cost of HPLC systems is expected to restrict market growth to a certain extent. A dearth of trained resources may also challenge market growth in the coming years.
Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=117899209 The global HPLC market is well established owing to the dominance of prominent market players, such as Waters (US), Agilent (US), Shimadzu (Japan), Thermo Fisher (US), PerkinElmer (US), GE Healthcare (US), Bio-Rad (US), Merck Millipore (Germany), Hitachi (Japan), Showa Denko (Japan), Gilson (US), Phenomenex (US), JASCO (US), Hamilton Company (US), SIELC (US), Orochem (US), YMC Co. Ltd. (Japan), Restek (US), Trajan Scientific (Australia), and Tosoh Bioscience LLC (Japan). Waters was the largest player in the HPLC market. The company has been operating in the life science and analytical instruments business since 1958. It is one of the pioneers in the field of HPLC and has managed to establish a brand of its own. Product launches and strategic collaborations and acquisitions will further augment its position in the market. The company has managed to establish a base of more than 40,000 customers around the world, and this figure is expected to grow in the coming years. The company’s HPLC products are used in pharmaceutical, industrial, and life science processes, such as drug discovery and development, clinical trial testing, nutritional safety analysis, and environmental testing. Agilent was the second-largest player in the global HPLC market. A large part of the company’s revenue is generated from its Life Sciences and Applied Markets and Agilent CrossLab segments. The growth of the company is attributed to strategic mergers and acquisitions, strategic transactions, and improved R&D and capital expenditure. Agilent’s strategy to launch multiple products for effective and efficient chromatography studies has ensured its growth in this market. Expansions undertaken by Agilent to introduce new research and logistics bases in Asian countries are expected to strengthen its position in this market further. The company sells the majority of its products through a direct sales force. Shimadzu was the third-largest player in the HPLC market. It operates under five business segments—Analytical Instruments, Medical Systems, Aircraft Equipment, Industrial Machinery, and Testing and Measuring Instruments. Around 65% of the company’s revenue is generated from its Analytical and Measuring Instruments segments. The company dominates the markets in Asia and Europe. It is operating successfully in the highly competitive analytical instruments market, primarily based on the ease of use, software compatibility, and the cost-efficiency of its products. Get 10% Customization on this Research Report:-https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=117899209 Other players operating in the HPLC market adopted the strategy of collaborations, contracts, agreements, partnerships, alliances, acquisitions, expansions, product launches, grants, accreditations, patents, and licensing to increase their customer base across geographies and establish a strong foothold in the market. Browse Related Reports: Chromatography Instruments Market by Type (Liquid Chromatography, Gas Chromatography), Consumable & Accessory (Columns, Detectors, Pressure Regulators), End User (Life Science Industry, Oil & Gas Industry), and Region - Analysis & Global Forecasts to 2025 https://www.marketsandmarkets.com/Market-Reports/chromatography-instrumentation-market-1258.html Growth in the flow cytometry market is largely driven by the rising global incidence and prevalence of HIV/AIDS and cancer, growing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the fields of immunology and immuno-oncology research, technological advancements, increasing incorporation of AI platforms in flow cytometry workflows, and increasing advancements in flow cytometry software. However, the high cost of flow cytometry products is a major factor hampering the growth of the market.
The flow cytometry market is projected to reach USD 6.3 billion by 2026 from USD 4.3 billion in 2021, at a CAGR of 8.1%. Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584 The prominent players in the global flow cytometry market include Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Luminex Corporation (US), Agilent Technologies, Inc. (US), Sony Group Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec GmbH (Germany), Enzo Biochem, Inc. (US), Sysmex Corporation (Japan), bioMérieux S.A. (France), Cytonome/ ST, LLC (US), Sartorius AG (Germany), Cytek Biosciences, Inc. (US), Union Biometrica, Inc. (US), Apogee Flow Systems Ltd. (UK), Stratedigm, Inc. (US), NanoCellect Biomedical, Inc. (US), On-chip Biotechnologies, Co., Ltd. (Japan), NEXCELOM BIOSCIENCE LLC (US), BennuBio Inc. (US), ORFLO Technologies (US), Bay Biosciences Co., Ltd. (Japan), BioLegend, Inc. (US), and CytoBuoy B.V (Netherlands). The analysis of market developments between 2018 and 2021 revealed that product launches and enhancements and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the flow cytometry market. Product launches and approvals were the most widely adopted growth strategies by market players. BECTON, DICKINSON AND COMPANY (US) BD is the leading player in the flow cytometry market. The company offers a significant number of products and consistently backs product launches with technological innovation. The company’s focus on innovative, user-friendly software solutions on flow cytometry has helped maintain its dominant position in the market. Request Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584 DANAHER CORPORATION (US) Danaher Corporation is one of the leading players in the flow cytometry market. It operates in the nuclear medicine market through its Beckman Coulter subsidiary. This company primarily strategizes its growth through acquisitions, key collaborations, and product launches. Beckman Coulter significantly contributes to Danaher’s revenue through innovative research, advancement, expansion, and the launch of novel flow cytometry products. The company has a significant number of product launches and acquisitions in the flow cytometry market, especially in 2019 and 2020. This indicates the company’s focused strategy to emerge as a leader in this market in the near future. Browse Related Reports: Cell Analysis Market by Product [Microscope, Spectrophotometers, Flow cytometry (Software, Accessories)], Process (Cell Viability, Cell Proliferation, Signal Transduction), End User (Pharma, Research, Biotechnology Companies) - Global Forecast to 2024 According to the new market research report "ECG Cables and Lead Wires Market by Material (Thermoplastic Elastomer, TPU), Usability (Reusable, Disposable), Type (12-Lead, 6-Lead, 5-Lead, 3-Lead), Patient Care Setting (Hospitals, ICUs, Home Care, Ambulatory) & Region - Global Forecast to 2026", published by MarketsandMarkets™, the global ECG Cables and Lead Wires Market is projected to reach USD 3.0 billion by 2026 from USD 2.1 billion in 2021, at a CAGR of 7.5%.
Browse in-depth TOC on "ECG Cables and Lead Wires Market" 199 – Tables 63 – Figures 268 – Pages Download PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34598493 The policy programs to provide effective care to patients with cardiovascular diseases (CVD), technological advancements, and the implementation of favorable government regulations and rising geriatric population. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the market. ECG lead wires and ECG cables segment accounted for the largest share of the ECG cables and lead wires market, by type segment, in 2020. ECG cables market is segmented into ECG lead wires and ECG cables. The ECG lead wires market is divided into 12-lead ECG lead wires, 5- lead ECG lead wires, 3-lead ECG lead wires, 6-lead ECG lead wires, single-lead ECG lead wire, and other ECG lead wires (15- and 18-lead ECG lead wires). In 2020, the 12-lead ECG lead wires segment accounted for the largest share of the ECG lead wires and ECG cables market. The large share of this segment can be attributed to the wide usage by paramedics to diagnose acute myocardial infarction (AMI) and reduce treatment time. TPE (thermoplastic elastomer) segment to register the highest growth rate during the forecast period. ECG cables and lead wires market is segmented into TPE (thermoplastic elastomer), TPU (thermoplastic polyurethane), and other materials (silicone and PVC). In 2020, the TPE segment accounted for the largest share of the ECG cables and lead wires. The large share of this segment can be attributed to the increased consistency, durability, shore hardness, and flexibility offered compared to other materials. Request Sample Pages: -https://www.marketsandmarkets.com/requestsampleNew.asp?id=34598493 Reusable cables and lead wires segment to register the highest growth rate during the forecast period. ECG cables market is segmented into reusable and disposable cables and lead wires. In 2020, the reusable cables and lead wires segment accounted for the largest share of the ECG cables and lead wires market. The huge share of this segment is mainly due to the low prices associated with the adoption of reusable cables and lead wires and because these types are majorly adopted in the developing regions. The hospitals & ICUs segment accounted for the largest share of the ECG cables and lead wires, by patient care setting segment, in 2020. Based on patient care setting, the lead wires market is segmented hospitals & ICUs, long-term care facilities, clinics, and ambulatory and home care centers. In 2020, hospitals & ICUs accounted for a larger share of the ECG cables and lead wires market. The large share of this segment can be attributed to the growing burden of cardiovascular diseases, which in turn is increasing the need for quality cardiology care. North America is the largest regional market for ECG cables and lead wires market. The global ECG cables market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The North American lead wires market growth can be attributed to the rapid increase in the aging population and rising cardiovascular disease rate as compared to other regions. The major players operating in this ECG Cables and Lead Wires Market are Cardinal Health, Inc. (US), 3M Company (US), Becton, Dickinson and Company (US), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), Abbott Laboratories (US), Boston Scientific Corporation (US), CONMED Corporation (US), OSI Systems, Inc. (US), Mindray Medical International Limited (China), Welch Allyn, Inc. (US), Curbell Medical Products, Inc. (US), Schiller AG (US), Siemens Healthineers AG (Germany), Dräger (Germany), Shanghai Berry Electronic Tech Co., Ltd (China), Unimed Medical Supplies Inc. (China), Amydi-med Electronic Technology Co., Ltd. (China), MedLink Electronics Tech Co. Ltd., (China), Sorimex (Poland), Nuova Gmbh (Germany), LUMED (Italy), UpnMed Equipment Co., Ltd.(China), Carlisle Medical Technologies (US), and LifeLine Medical, Inc. (US). The major factors driving the growth of this market include the increasing government funding to support genomics projects, the growing incidence of cancer and increasing applications of NGS in cancer research, the entry of new players and start-ups in the genomics market, and the growing application areas of genomics.
The global Genomics Market is projected to reach USD 54.4 billion by 2025 from USD 22.7 billion in 2020, at a CAGR of 19.0% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=613 Market Segmentation:- The next generation sequencing sub segment accounted for the largest share of the sequencing technology segment in the genomics market in 2019. Based on technology, the genomics market is segmented into sequencing technologies, PCR, nucleic acid extraction and purification, microarrays, and other technologies. The sequencing segment is further sub segmented into next-generation sequencing (NGS) and other sequencing technologies. In 2019 the next-generation sequencing technology accounted for the largest share of the genomics market. The advantages associated with NGS such as ultra-high-throughput, scalability, and high speed, enable researchers to perform a wide variety of applications, including animal breeding, agriculture, and human genomics. This is one of the major drivers of this segment. The hospitals and clinics segment accounted for the largest share of the end user segment in the genomics market in 2019. Based on end users, the genomics market is segmented into hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies, and other end users. In 2019, the hospitals & clinics segment accounted for the largest share of the market. Hospitals & clinics are shifting from traditional genomic testing methods to cost-effective and more sensitive methods, such as whole-exome sequencing, which is a major factor driving the market growth. Market Drivers: – 1 Rising Government Funding and Growth in the Number of Genomics Projects 2 Growing incidence of cancer and increasing applications of next-generation sequencing in cancer research 3 Growing Application Areas of Genomics 4 Entry of New Players and Start-Ups in the Genomics Market Regional Analysis: - In 2019, the Asia Pacific region accented for the fastest growing region of the genomics market. It is also estimated to grow at the highest CAGR in the genomics market during the forecast period, mainly due to favorable government support for genomics projects, increasing awareness about newer genomics technologies such as NGS, and expansions of key players to strengthen their presence in the APAC region. Request for sample Pages :-https://www.marketsandmarkets.com/requestsampleNew.asp?id=613 Top key Players:- Some of the leading players operating in the genomics market are Illumina, Inc. (US), Thermo Fisher Scientific (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), and BGI (China). According to the new market research report "Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Global Forecasts to 2026", published by MarketsandMarkets™, the global market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period.
Browse and in-depth TOC on "Stem Cell Therapy Market" 142 - Tables 45 - Figures 160 - Pages Download PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48 The Market growth is driven mainly by factors such as increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market. The adipose tissue-derived MSCs segment accounted for the largest share of the cell source segment in the Stem Cell Therapy Market in 2020. Based on the cell source from which stem cells are obtained, the global market is segmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which includes human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). In 2020, adipose tissue-derived MSCs accounted for the markets largest share due to their increasing utilization in treating inflammatory diseases and wounds & injuries. There are several associated advantages, such as ease of harvesting stem cells by minimally invasive methods, simplicity of the isolation procedure, and better quality & proliferation capacity of adipose tissue-derived stem cells. The musculoskeletal disorders segment accounted for the largest share of the therapeutic application segment in the Stem Cell Therapy Market in 2020 Based on therapeutic application, the global market is segmented into musculoskeletal disorders, wounds & injuries, cardiovascular diseases, surgeries, inflammatory & autoimmune diseases, neurological disorders, and other therapeutic applications (which include ocular diseases, fat loss, and peripheral arterial diseases). In 2020, the musculoskeletal disorders segment accounted for the largest share of the therapeutic application segment. The large market share of this segment is attributed to the increasing prevalence of musculoskeletal disorders such as osteoarthritis, bone repair, and regeneration Get Data as per your Format and Definition | REQUEST FOR CUSTOMIZATION:- https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=48 The Asia Pacific region is the fastest-growing region of the Stem Cell Therapy Market in 2020. The Asia Pacific region is estimated to grow at the highest CAGR in the market during the forecast period. Some of the major factors fueling the growth of the APAC market include regulatory approvals and guidelines for product approvals and the presence of major stem cell players in countries such as South Korea, Japan, India, and Australia. Key players in the Stem Cell Therapy Market include Smith & Nephew (UK), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), PHARMICELL Co., Ltd. (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), and NuVasive, Inc. (US). Browse Related Reports: Nerve Repair and Regeneration Market by Products (Nerve Conduits, Nerve Wraps, Vagus Nerve Stimulation, Sacral Nerve Stimulation, Spinal Cord Stimulation, TENS, TMS), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) - Global Forecast to 2025 https://www.marketsandmarkets.com/Market-Reports/nerve-repair-regeneration-market-883.html |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |